Intelligent Bio Solutions (INBS) announced the successful completion of its method comparison study its Intelligent Fingerprinting Drug Screening System. The Method Study confirmed the sensitivity, specificity, accuracy, and usability of the System, validating its potential for use in workplace drug testing and other applications. This milestone follows INBS’ recently announced strong initial results from its Pharmacokinetic study, both of which are key achievements on the path to the Company’s FDA 510(k) submission.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions Announces Study Results and Stock Sale
- Intelligent Bio Solutions announces ‘strong initial results’ from PK study
- Intelligent Bio Solutions reports Q1 EPS (70c) vs. ($12.84) last year
- Intelligent Bio partners with B2i Digital to amplify investor outreach
- Intelligent Bio Solutions reports Q1 preliminary revenue $0.87M
